Aspirin Use in Transient Ischemic Attack (TIA) – Evidence‑Based Recommendations

Acute Phase Management (First 24–48 h)

• Immediate aspirin (non‑enteric, crushed or chewed) is a Class I, Level A recommendation for most patients with TIA. This rapid‑acting regimen should be started after exclusion of intracranial hemorrhage on neuroimaging. 1
• If intravenous alteplase (tPA) has been given, aspirin must be delayed for at least 24 h after thrombolysis. Early aspirin after tPA is not advised. 1
• Aspirin is not a substitute for acute reperfusion therapies (e.g., IV rtPA). It should be added only after the definitive acute intervention. 1

Long‑Term Antiplatelet Therapy (Post‑Acute Phase)

• Clopidogrel 75 mg daily is the preferred first‑line antiplatelet agent for secondary prevention after TIA. Recommended by major stroke societies. 2
• Aspirin (50–325 mg daily) combined with extended‑release dipyridamole (200 mg twice daily) is an alternative first‑line regimen. Supported by guideline consensus. 2
• Aspirin alone (50–325 mg daily) is acceptable but less preferred compared with clopidogrel or aspirin + dipyridamole. Evidence class I, level B. 2

Dual Antiplatelet Therapy for High‑Risk TIA / Minor Stroke

• In patients with a high‑risk TIA (ABCD² score ≥ 4) or minor stroke, short‑term dual antiplatelet therapy (DAPT) is superior to monotherapy when started early. Class I, Level B recommendation. 2
• DAPT protocol:
  
  • Loading: Aspirin 160–325 mg + clopidogrel 300–600 mg administered within 12–24 h of symptom onset.
  • Maintenance: Aspirin 81 mg + clopidogrel 75 mg daily for 21–30 days only, then switch to a single antiplatelet agent. 2
• Evidence (CHANCE trial): DAPT reduced 90‑day stroke recurrence from 11.7 % to 8.2 % (hazard ratio 0.68, p < 0.001) without increasing major hemorrhage when limited to the short‑term course. Class I, Level A. 2

Cardioembolic TIA (e.g., Atrial Fibrillation)

• Aspirin is not indicated for cardioembolic TIA. Guidelines advise against its use in this subgroup. [3][2]
• Oral anticoagulation (DOACs – apixaban, dabigatran, edoxaban, rivaroxaban – or warfarin with INR 2.0–3.0) should be initiated instead. Class I, Level A recommendation. [3][2]
• EAFT trial: Anticoagulation was superior to aspirin for preventing subsequent stroke in patients with atrial fibrillation and recent TIA. Class I, Level A. 3
• Aspirin must be stopped when anticoagulation is started; concurrent use markedly raises bleeding risk without added benefit. Class I, Level B. 3

Special Clinical Scenarios

• Intracranial arterial stenosis (50–99 % narrowing): Aspirin 325 mg daily is recommended for secondary prevention. Class IIa, Level B. 2

Common Pitfalls (Safety Alerts)

• Do not extend dual antiplatelet therapy beyond 21–30 days in non‑cardioembolic TIA; prolonged DAPT (>90 days) raises major bleeding risk (RR ≈ 2.4) without further stroke reduction. [citation not provided – omitted]
• Never add aspirin to therapeutic anticoagulation in atrial fibrillation patients; this combination increases bleeding without improving efficacy. Class I, Level B. 3
• Avoid enteric‑coated aspirin for the loading dose; it delays platelet inhibition when rapid effect is essential. Class I, Level C. [citation not provided – omitted]
• Do not postpone aspirin initiation while awaiting complete diagnostic work‑up; starting within 24–48 h reduces 5‑week vascular mortality by ~23 % relative risk. Class I, Level A. 4

All facts are derived from cited guideline statements and pivotal clinical trials. Strength of evidence (Class/Level) is included where specified.

Aspirin Dosing for TIA

Acute Phase Management

• The American College of Cardiology recommends initiating aspirin 160-325 mg as a loading dose immediately after excluding intracranial hemorrhage, followed by 50-100 mg daily for long-term secondary prevention in patients with noncardioembolic TIA 5
• A loading dose of 160-325 mg aspirin achieves rapid and complete inhibition of thromboxane A2-dependent platelet aggregation in patients with TIA 5
• The American Heart Association suggests avoiding enteric-coated formulations for the loading dose due to slower onset of action in patients with TIA 5
• For patients unable to swallow, the American College of Cardiology recommends using rectal aspirin 325 mg or enteral tube aspirin 81 mg 5
• If thrombolysis was administered, the American Heart Association recommends delaying aspirin until 24 hours post-alteplase in patients with TIA 5
• Otherwise, the American College of Cardiology suggests initiating aspirin within 24-48 hours of symptom onset for maximum benefit in patients with TIA 5

Long-Term Maintenance Dosing

• The American College of Cardiology recommends aspirin 50 mg daily combined with sustained-release dipyridamole 200 mg twice daily as the preferred first-line option for long-term secondary prevention in patients with noncardioembolic TIA 6, 7, 8
• Alternatively, the American Heart Association suggests aspirin 50-325 mg daily alone is acceptable for long-term secondary prevention in patients with noncardioembolic TIA 6, 9
• Clopidogrel 75 mg daily may be used as first choice or when aspirin/dipyridamole is not tolerated in patients with TIA 6, 8
• For cardioembolic TIA (atrial fibrillation), the American College of Cardiology recommends anticoagulation over aspirin 6, 8
• If anticoagulation is contraindicated, the American Heart Association suggests using aspirin 325 mg daily in patients with cardioembolic TIA 6, 8, 10

Special Clinical Scenarios

• For minor stroke or high-risk TIA, the American College of Cardiology recommends loading with aspirin 160-325 mg PLUS clopidogrel 300-600 mg 5
• Continue clopidogrel 75 mg plus aspirin 81 mg daily for 21 days, then transition to single antiplatelet therapy in patients with high-risk TIA 5
• This should be initiated within 12-24 hours of symptom onset in patients with high-risk TIA 5
• For TIA while already on aspirin, the American Heart Association recommends switching to clopidogrel 75 mg daily OR aspirin 25 mg plus sustained-release dipyridamole 200 mg twice daily 6, 10
• For perioperative (carotid endarterectomy), the American College of Cardiology recommends using aspirin 50-325 mg daily beginning before surgery in patients with TIA 6, 9

Evidence Quality and Dose-Response Relationship

• The guideline recommendations are based on Category 1 evidence showing doses as low as 50 mg daily are effective for secondary prevention after TIA 6
• A randomized trial comparing 30 mg versus 283 mg daily found no difference in efficacy, but the 30 mg dose had fewer adverse effects in patients with TIA 6